SLP Strangle Strategy
SLP (Simulations Plus, Inc.), in the Healthcare sector, (Medical - Healthcare Information Services industry), listed on NASDAQ.
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs.
SLP (Simulations Plus, Inc.) trades in the Healthcare sector, specifically Medical - Healthcare Information Services, with a market capitalization of approximately $367.7M, a beta of 1.33 versus the broader market, a 52-week range of 11.09-21.01, average daily share volume of 439K, a public-listing history dating back to 1997, approximately 243 full-time employees. These structural characteristics shape how SLP stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.33 indicates SLP has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. SLP pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on SLP?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current SLP snapshot
As of June 30, 2026, spot at $18.30, ATM IV 15.30%, IV rank 1.61%, expected move 4.39%. The strangle on SLP below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on SLP specifically: SLP IV at 15.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a SLP strangle, with a market-implied 1-standard-deviation move of approximately 4.39% (roughly $0.80 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SLP expiries trade a higher absolute premium for lower per-day decay. Position sizing on SLP should anchor to the underlying notional of $18.30 per share and to the trader's directional view on SLP stock.
SLP strangle setup
The SLP strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SLP near $18.30, the first option leg uses a $19.22 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SLP chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SLP shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $19.22 | N/A |
| Buy 1 | Put | $17.39 | N/A |
SLP strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
SLP strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on SLP. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on SLP
Strangles on SLP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SLP chain.
SLP thesis for this strangle
The market-implied 1-standard-deviation range for SLP extends from approximately $17.50 on the downside to $19.10 on the upside. A SLP long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SLP IV rank near 1.61% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on SLP at 15.30%. As a Healthcare name, SLP options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SLP-specific events.
SLP strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SLP positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SLP alongside the broader basket even when SLP-specific fundamentals are unchanged. Always rebuild the position from current SLP chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on SLP?
- A strangle on SLP is the strangle strategy applied to SLP (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SLP stock trading near $18.30, the strikes shown on this page are snapped to the nearest listed SLP chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SLP strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SLP strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 15.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SLP strangle?
- The breakeven for the SLP strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SLP market-implied 1-standard-deviation expected move is approximately 4.39%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on SLP?
- Strangles on SLP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SLP chain.
- How does current SLP implied volatility affect this strangle?
- SLP ATM IV is at 15.30% with IV rank near 1.61%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.